Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259146 | 0.89 | ALDH1A1 (0.32) | CA2ALDH1A1TP53HSD17B10 | |
| SCHEMBL4357945 | 0.86 | ALDH1A1 (0.36) | CA2ALDH1A1TP53HSD17B10 | |
| SCHEMBL16572452 | 0.85 | ALDH1A1 (0.34) | ALDH1A1TP53HSD17B10 | |
| SCHEMBL277661 | 0.84 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL8557919 | 0.82 | — | — | |
| SCHEMBL9237706 | 0.81 | CA2 (0.40) | CA2ALDH1A1TP53HSD17B10 | |
| Ethylene Glycol SCHEMBL27885940 | 0.80 | TSHR (0.33) | ALDH1A1TP53MAPK1HSD17B10 | |
| SCHEMBL17453659 | 0.78 | TSHR (0.43) | ALDH1A1TP53MAPTMAPK1HTT | |
| SCHEMBL8780035 | 0.78 | CA2 (0.30) | CA2 | |
| SCHEMBL8948892 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008941-A1 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9481706-B2 | Purification of non-glycosylated polypeptides | HOFFMANN-LA ROCHE INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-8889837-B2 | Purification of pegylated polypeptides | HOFFMAN-LA ROCHE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140220633-A1 | PURIFICATION OF NOT-GLYCOSYLATED POLYPEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8795533-B2 | Chromatographic methods | HOFFMANN-LA ROCHE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140163207-A1 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN | HOFFMANN-LA ROCHE INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130190478-A1 | PURIFICATION OF NOT-GLYCOSYLATED POLYPEPTIDES | HOFFMANN-LA ROCHE INC. | 2013-07-25 | — | — | US | disclosed |
| US-20120197007-A1 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | US | disclosed |
| US-8138317-B2 | Purification of pegylated polypeptides | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110118448-A1 | Purification of pegylated polypeptides | BURG JOSEF | 2011-05-19 | — | — | US | disclosed |
| US-7846896-B2 | PEG conjugates of NK4 | HOFFMAN-LA ROCHE INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846336-B2 | regeneration of a cation exchange chromatography column for purification of polypeptides | HOFFMANN-LA ROCHE INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090118476-A1 | Purification of pegylated polypeptides | HOFFMANN-LA ROCHE INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090101585-A1 | regeneration of a cation exchange chromatography column for purification of polypeptides | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7459436-B2 | Treatment of disturbances of iron distribution | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459429-B2 | Method of treating disturbances of iron distribution in inflammatory intestinal diseases | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459435-B2 | Treatment of disturbances of iron distribution | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080085857-A1 | conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 | BRANDT MICHAEL | 2008-04-10 | — | — | US | disclosed |
| US-7202208-B2 | Erythropoietin composition | HOFFMAN-LA ROCHE INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7169754-B2 | Erythropoietin composition | HOFFMANN-LA ROCHE INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220633-A1 | PURIFICATION OF NOT-GLYCOSYLATED POLYPEPTIDES | YIPF5, HASPIN, HM13 | CA1 424/4885CA2 778/4885NPC1 3319/4885 |
| US-20120197007-A1 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN | EPOR, TFRC, RPS27A | CA1 2423/4885CA2 3812/4885NPC1 2546/4885 |
| US-20140163207-A1 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN | EPOR, TFRC, RPS27A | CA1 2423/4885CA2 3812/4885NPC1 2546/4885 |
| US-20170008941-A1 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN | EPOR, TFRC, RPS27A | CA1 2423/4885CA2 3812/4885NPC1 2546/4885 |
| US-20130190478-A1 | PURIFICATION OF NOT-GLYCOSYLATED POLYPEPTIDES | YIPF5, HASPIN, HM13 | CA1 488/4885CA2 827/4885NPC1 3350/4885 |
| US-20090118476-A1 | Purification of pegylated polypeptides | EPOR, HAMP, EGFR | CA1 2221/4885CA2 1428/4885NPC1 1834/4885 |
| US-20080085857-A1 | conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 | PBK, IL4, CD47 | CA1 2232/4885CA2 3517/4885NPC1 2651/4885 |
| US-20110118448-A1 | Purification of pegylated polypeptides | EPOR, HAMP, EGFR | CA1 2221/4885CA2 1428/4885NPC1 1834/4885 |
| US-20090101585-A1 | regeneration of a cation exchange chromatography column for purification of polypeptides | IAPP, HDGF, HGF | CA1 507/4885CA2 258/4885NPC1 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.